Evidence map›Paper›PMID 40813437›Full record

ReviewNPJ precision oncology2025

A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizon.

Cameron Crowell, Ziwen Zhu, Yingxiang Li, Maria L Varela, Quinn Ostrom, Patrick J Cimino, Sohil H Patel, Suzanne J Baker, Chetan Bettegowda, Houtan Noushmehr and 21 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Cameron CrowellDivision of Hematology and Oncology, IWK Health Centre, Halifax, NS, Canada.
Ziwen ZhuDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Yingxiang LiDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Maria L VarelaDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Quinn OstromNeurosurgery, Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Patrick J CiminoSurgical Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.
Sohil H PatelRadiology and Medical Imaging Department, University of Virginia Health, Charlottesville, VA, USA.
Suzanne J BakerCenter for Excellence in Neuro-Oncology Sciences, Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Chetan BettegowdaDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Houtan NoushmehrHermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA.
Claudia L KleinmanMcGill Centre for Translational Research in Cancer, Lady Davis Institute for Medical Research, McGill University, Montreal, QC, Canada.
Laura CantyThe Hospital for Sick Children, Toronto, ON, Canada.
Gustavo Alencastro Veiga CruzeiroDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Anandani NellanPediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA.
Oren BecherPediatric Hematology, Mount Sinai Medical, New York, NY, USA.
Tom B DavidsonCancer and Blood Disease Institute, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Dolores HambardzumyanOncological Sciences and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Adam GreenMorgan Adams Foundation Pediatric Brain Tumor Research Program, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.
Robert ThorneDenali Therapeutics, South San Francisco, CA, USA.
Kelli WilsonDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, NIH, Rockville, MD, USA.
Brett TheelerUniformed Services University, School of Medicine, Bethesda, MD, USA.
Jason GregoryUniformed Services University, School of Medicine, Bethesda, MD, USA.
Peter MathenRadiation Oncology Branch, National Cancer Institute, Bethesda, MD, USA.
Nadia BiassouNIH Radiation Department, Bethesda, MD, USA.
Sheila McTheniaChildren's Healthcare of Atlanta, Atlanta, GA, USA.
Craig ErkerDivision of Hematology and Oncology, IWK Health Centre, Halifax, NS, Canada.
Robert GalvinDepartment of Pediatrics, Division of Pediatric Hematology-Oncology, University of Minnesota, Minneapolis, MN, USA.
Ariane SoldatosNINDS Consult Service, National Institutes of Health, Bethesda, MD, USA.
Pedro R LowensteinDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Maria G CastroDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Sadhana JacksonSurgical Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA. Sadhana.jackson@nih.gov.

Funding

Uncover the role of H3.3-G343R mutation in shaping the DNA damage response, anti-tumor immunity and mechanisms of resistance in glioma.R01NS122165 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Maria G Castro · 2022 to 2026
$2.5M
ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomasR01CA255788 · NCI · DUKE UNIVERSITY · PI WAITKUS, MATTHEW · 2022 to 2025
$1.9M
NCI NIH HHS R01 CA255788NINDS NIH HHS R01 NS122165
6 · The paper itself

Abstract

Diffuse hemispheric glioma H3 G34-mutant is primarily diagnosed in adolescents/young adults. While molecular diagnostics have improved, cellular mechanisms that drive tumor progression and therapy resistance are poorly understood. Combining previous published studies with findings from the 2024 NIH G34-mutant symposium aid in summarizing translational and clinical updates on disease development, cellular repair processes, and the immune microenvironment. This collective work is meant to outline opportunities for treatment and prolonged survival.

Identifiers

PMID40813437
PMCPMC12354862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.